Mining Emerging Biomedical Literature for Understanding Disease Associations in Drug Discovery
Systematically evaluating the exponentially growing body of scientific literature has become a critical task that every drug discovery organization must engage in in order to understand emerging trends for scientific investment and strategy development. Developing trends analysis uses the number of publications within a 3-year window to determine concepts derived from well-established disease and gene ontologies to aid in recognizing and predicting emerging areas of scientific discoveries relevant to that space. In this chapter, we describe such a method and use obesity and psoriasis as use-case examples by analyzing the frequency of disease-related MeSH terms in PubMed abstracts over time. We share how our system can be used to predict emerging trends at a relatively early stage and we analyze the literature-identified genes for genetic associations, druggability, and biological pathways to explore any potential biological connections between the two diseases that could be utilized for drug discovery.
Conclusion: Serum LCN2 concentration is associated with the degree of itch in patients with psoriasis, suggesting that serum LCN2 may be a useful clinical marker for itch in psoriasis. PMID: 30805373 [PubMed - in process]
Authors: Chiricozzi A, Gisondi P, Girolomoni G Abstract INTRODUCTION: Psoriasis is a chronic inflammatory skin disease that is increasingly being recognized as a complex disorder affecting multiple systems. Systemic inflammation is considered the pathogenic link between psoriasis and its comorbid conditions that include arthritis, metabolic disorders, depression, and cardiovascular diseases. The presence of comorbid conditions modifies both its clinical management and the therapeutic approach in psoriatic patients. Areas covered: This review describes the clinical, epidemiological, and pathogenic link between psori...
Conclusion: The serum levels of adropin in psoriasis patients were significantly lower in the presence of MetS, and this decrease was more prominent than in those without MetS. Adropin may be a contributing factor for metabolic disorders and the development of MetS in psoriasis patients. PMID: 30762319 [PubMed - in process]
Conclusion: Psoriatic patients, carriers of risk allele of FTO gene rs9939609, have an increased risk for more severe psoriasis and obesity and may develop obesity-induced insulin resistance. PMID: 30733965 [PubMed - in process]
Abstract CLINICAL QUESTION: Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis (PsA) in obese individuals? BACKGROUND: Obesity presents a rising public health challenge and is more prevalent amongst individuals with psoriasis or PsA compared to the general population. Longitudinal population-based studies suggest a causal role for obesity in psoriasis and PsA onset and that obesity drives greater disease severity. METHODS: We systematically reviewed evidence within Medline/EMBASE/CENTRAL databases and clinical trials registries examining lifestyle, pharmacological and ...
Abstract BACKGROUND: Long-term therapy of psoriasis is impaired by gradual loss of effectiveness and treatment discontinuation. Identifying factors that affect biologic drug survival may help in treatment optimization. OBJECTIVES: To identify factors that predicted biologic drug persistence or discontinuation in a real-life setting. METHODS: We identified the studies of biologic persistence in psoriasis through a comprehensive, systematic literature search using pre-defined search criteria and screened by title/abstract then further by full-text review. Hazard ratio (HR) data were extracted for all avail...
ConclusionsOur study, using genetic variants as instrumental variables for BMI, provides evidence that higher BMI leads to a higher risk of psoriasis. This supports the prioritization of therapies and lifestyle interventions aimed at controlling weight for the prevention or treatment of this common skin disease. Mechanistic studies are required to improve understanding of this relationship.
te; E Abstract INTRODUCTION: Psoriasis is associated with a higher risk of cardiovascular and/or metabolic comorbidity in adults, but discordant data have been reported in children. OBJECTIVE: To evaluate the frequency of metabolic and cardiovascular comorbidity in children with psoriasis and to establish whether age at onset of psoriasis correlates with metabolic and cardiovascular comorbidity in adulthood. MATERIAL AND METHODS: We conducted a systematic review on MEDLINE, using PubMed and Ovid. The search was limited to children (
PMID: 30604555 [PubMed - in process]
Psoriasis is a disease with systemic inflammation and accompanied by multiple comorbidities, including metabolic syndrome and obesity (Hwang et al., 2017; Tsai et al., 2017; Yu et al., 2017). Obesity is often observed in patients with psoriasis and may precede development of psoriasis (Debbaneh et al., 2014). Western diet (WD) plays a crucial role in the development of obesity in Western countries and is characterized by elevated amoun ts of fat and sugars, especially simple sugars such as sucrose (Jena et al., 2017).